Table 1.
Tumor incidence in limiting dilution assay
| No. of cells injected | Tumor incidence | |||
|---|---|---|---|---|
| Placebo | ATO + ATRA | Parental | CRISPR | |
| 102 | 5/6 | 0/6 | — | — |
| 103 | 4/5 | 2/4 | 4/5 | 0/5 |
| 104 | 5/5 | 4/6 | 5/5 | 0/5 |
| 105 | 4/4 | 5/6 | 5/5 | 1/5 |
| BCSC frequency | 1 in 252 | 1 in 22,644 | 1 in 621 | 1 in 503,345 |
| 95% CI | 1 in 88–1 in 722 | 1 in 8,220–1 in 62,382 | 1 in 209–1 in 1,847 | 1 in 71,332–1 in 3,551,801 |
231 xenografts from mice treated with placebo or ATO plus ATRA or parental or CRISPR 231 cells were dissociated into single-cell suspensions and injected into the flank of mice in limiting dilution. Tumor formation were observed for 6 weeks after inoculation. CSC frequency was calculated using the L-Calc software